The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert warning healthcare providers and the general public about the circulation of counterfeit Augmentin 625mg tablets in Nigeria.
In Public Alert No. 024/2026, the agency disclosed that the falsified medicine—packaged as Augmentin 625mg tablets (2 x 7 tablets) with Batch No. AC3N—was flagged following multiple complaints received by the genuine manufacturer, GlaxoSmithKline (GSK).
According to NAFDAC, GSK conducted an investigation and confirmed the product to be counterfeit after reviewing documentary evidence, photographs, and a social media video.
Although the fake product bears the same batch number as an authentic supply previously distributed in Nigeria, discrepancies in manufacturing and expiry dates exposed it as falsified.
The original batch AC3N, NAFDAC said, was manufactured at GSK’s Worthing facility in the United Kingdom on August 23, 2023, and packaged between September 19 and 20, 2023.
However, the suspect product falsely indicates a manufacturing date of September 2025 and an expiry date of September 2028—details that do not align with GSK’s production records.
Further examination also revealed packaging inconsistencies, including textual errors and poor sealing quality, reinforcing findings that the product is not genuine.
Augmentin, a widely used antibiotic containing amoxicillin and clavulanic acid, is prescribed for the treatment of bacterial infections. NAFDAC warned that counterfeit versions may contain incorrect dosages, no active ingredients, or even harmful substances, posing serious health risks to patients.
The agency has urged healthcare professionals to immediately review their stock in hospitals, clinics, and pharmacies, quarantine any suspected counterfeit products, and halt their distribution.
NAFDAC also advised the public to remain vigilant and report any suspected falsified medicines or medical devices to the nearest NAFDAC office. Reports can also be made via its toll-free number, 0800-162-3322, or through email at [email protected].
The agency reaffirmed its commitment to safeguarding public health and ensuring that only safe, effective, and quality medicines are available in Nigeria.
- Nigeria gains investor confidence after S&P upgrades - May 16, 2026
- Who is ISIS ‘number two’ Abu Bilal al-Minuki - May 16, 2026
- Edoho, estranged wife trade allegations over failed marriage - May 16, 2026
